Lifesciences Giant Amgen Appoints Naveen Gullapalli as MD for Hyd Tech & Innovation Hub

He joins Amgen from Novartis, where he was instrumental in establishing and expanding the company’s Global Centre in Hyderabad, along with five other centers globally.

Global biotechnology leader Amgen has appointed Naveen Gullapalli as Managing Director of Amgen India, emphasizing its commitment to innovation and technology from its Hyderabad-based hub.

Gullapalli brings extensive expertise in global operations across pharmaceuticals, finance, and technology.

He joins Amgen from Novartis, where he was instrumental in establishing and expanding the company’s Global Centre in Hyderabad, along with five other centers globally.

His leadership drove innovation and strategic growth in these roles.

Som Chattopadhyay, National Executive for India at Amgen, highlighted the significance of the Hyderabad hub in the company’s global vision.

“Amgen India is key to furthering our global vision of unlocking the convergence of biotech and tech to accelerate innovation. Naveen’s strategic leadership will drive the success of this new site,” Chattopadhyay said.

Hyderabad: A Global Innovation Hub

The Hyderabad facility, announced in August 2024, forms a crucial part of Amgen’s global strategy to harness digital transformation and innovation.

Located in HITEC City, the center spans six floors at RMZ Spire Tower 110 and will accommodate up to 3,000 employees.

The hub focuses on scaling advanced technologies, including artificial intelligence, data science, and life sciences, to enhance operational efficiency and support Amgen’s mission of serving patients worldwide.

Hyderabad was selected for its robust talent pool in medicine, life sciences, and technology.

Amgen’s Global Presence & Vision

With a workforce of nearly 27,000 employees across approximately 100 countries, Amgen remains a leader in the biotech industry.

Over its 40-year history, the company has developed a broad pipeline of treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions.

Gullapalli’s leadership is set to strengthen Amgen India’s role in advancing biotech innovation on a global scale.

Stay tuned for more such updates on Digital Health News.